^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    EGFR inhibitor

    Related drugs:
    20h
    COLOSOTO: 5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab (clinicaltrials.gov)
    P2, N=300, Not yet recruiting, Federation Francophone de Cancerologie Digestive
    Trial initiation date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    5-fluorouracil • Vectibix (panitumumab) • Lumakras (sotorasib)
    1d
    Osimertinib-induced interstitial lung disease insights from faers signal detection and network toxicology analysis. (PubMed, BMC Cancer)
    1 Article types. Original Research.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib)
    3d
    COCOON: Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (clinicaltrials.gov)
    P2, N=305, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting
    Enrollment closed • Adverse events
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR L858R • EGFR exon 19 deletion
    |
    Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) • minocycline
    3d
    Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=38, Active, not recruiting, Australasian Gastro-Intestinal Trials Group | Recruiting --> Active, not recruiting | N=90 --> 38 | Trial primary completion date: Apr 2026 --> Jan 2026
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS wild-type • RAS wild-type
    |
    Erbitux (cetuximab) • Vectibix (panitumumab)
    3d
    RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer (clinicaltrials.gov)
    P=N/A, N=6, Active, not recruiting, Australasian Gastro-Intestinal Trials Group | Recruiting --> Active, not recruiting | Phase classification: P2 --> PN/A | N=75 --> 6 | Trial completion date: Jun 2025 --> Dec 2027 | Trial primary completion date: Jun 2024 --> Dec 2025
    Enrollment closed • Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan
    3d
    Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer (clinicaltrials.gov)
    P1, N=30, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E
    |
    Erbitux (cetuximab) • Braftovi (encorafenib) • ZEN-3694
    3d
    Toward targeting the untargetable: A non-canonical EGFR-peptide-drug conjugate achieves potent antitumor activity in KRAS-mutant CRC. (PubMed, J Control Release)
    PDC treatment significantly suppresses tumor growth in in vivo KRAS mutant xenograft model, demonstrating superior efficacy compared with cetuximab-based regimens and controls, without observable body weight loss. This strategy uses EGFR as a delivery portal instead of a signaling target, enabling KRAS independent anti-tumor activity. These findings indicate a non-canonical EGFR mediated delivery approach with potential translational relevance for the treatment of therapy resistant CRC.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Erbitux (cetuximab)
    3d
    Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial. (PubMed, J Clin Oncol)
    Ficerafusp alfa plus pembrolizumab demonstrated favorable safety and tolerability with promising antitumor activity in the first-line treatment of R/M HNSCC, particularly in those with HPV-negative tumors.
    P1 data • Journal • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • ficerafusp alfa (BCA101)
    3d
    WU-KONG36: Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Sichuan University | Trial completion date: Feb 2026 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L858R + EGFR exon 19 deletion
    |
    Zegfrovy (sunvozertinib)
    4d
    Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion). (PubMed, Lung Cancer)
    Although the primary endpoint was not met, the combination provided durable control of MPE and was well tolerated, suggesting potential value in symptom-focused management of this high-risk subgroup.
    P2 data • Journal • Pleural effusion
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    erlotinib • Cyramza (ramucirumab)
    4d
    Comparative Study of EnliTuo® Before and After Technology Change in Healthy Male Volunteers (clinicaltrials.gov)
    P1, N=86, Active, not recruiting, Taizhou Mabtech Pharmaceutical Co.,Ltd | Recruiting --> Active, not recruiting | Trial completion date: Feb 2026 --> May 2026
    Enrollment closed • Trial completion date
    |
    Enlituo (cetuximab biosimilar)
    4d
    OB-001 Enhances Osimertinib Brain Penetration: Preclinical Pharmacokinetics and Translational Rationale for EGFR-Mutant NSCLC with CNS Disease. (PubMed, Cancer Res Commun)
    OB-001, a KinetiSol® amorphous solid dispersion formulation of elacridar, was developed to overcome poor bioavailability of crystalline elacridar and evaluated as a strategy to enhance osimertinib brain delivery. OB-001 selectively boosts osimertinib brain exposure while sparing systemic PK. These preclinical data support further evaluation of OB-001 as a strategy to enhance CNS efficacy of osimertinib in EGFR-mutant NSCLC.
    PK/PD data • Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • elacridar (GF120918)